Fenostad 67 is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:
- Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
- Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.
- Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled.
- The recommended dose is 200 mg daily administered as one capsule of Fenostad 67 three times a day.
- The dose can be titrated up to 267 mg daily administered as one capsule of Fenostad 67, four times a day, if required. This maximum dose is not recommended in addition to a statin.
Elderly patients (≥ 65 years old)
- No dose adjustment is necessary, except for decreased renal function with eGFR < 60 mL/min/1.73 m2.
- eGFR < 30 mL/min per 1.73 m2: Fenofibrate should not be used.
- eGFR is between 30 and 59 mL/min per 1.73 m2: Should not exceed 100 mg standard or 67 mg micronized once daily. If the eGFR decreases persistently to < 30 mL/min per 1.73 m2, fenofibrate should be discontinued.
- Fenofibrate is not recommended.
- One capsule (67 mg) micronised fenofibrate/day/20 kg body weight.
- Fenostad 67 should be swallowed whole during a meal.